New possibilities for lipid level control using inclisiran — prospects for interaction between a cardiologist and a neurologist
Dyslipidemia is one of the most significant modifiable cardiovascular risk factors. The change in the modern paradigm for dyslipidemia treatment from high-intensity statin therapy to high-intensity lipid-lowering therapy makes it possible to more often use new drug classes to achieve the target leve...
Saved in:
| Main Authors: | A. B. Skiba, M. V. Menzorov, V. D. Puchek, I. M. Buchin, I. I. Polyakov, E. N. Menzorova |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2023-12-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/2977 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Innovative lipid-lowering therapy: experience of inclisiran use in the Republic of Belarus
by: E. A. Medvedeva, et al.
Published: (2023-05-01) -
Effectiveness of inclisiran lipid-lowering therapy in patients with atherosclerotic cardiovascular disease in Moscow healthcare
by: A. I. Sapina, et al.
Published: (2024-06-01) -
Lipoprotein(a) as a risk factor for cardiovascular diseases - focus on ischemic stroke (a position paper)
by: Ia. B. Skiba, et al.
Published: (2024-06-01) -
Observational study of inclisiran effectiveness in Moscow healthcare
by: A. I. Sapina, et al.
Published: (2023-12-01) -
Triple Non-Statin Therapy with Ezetimibe, Inclisiran, and Bempedoic Acid in Patients with Genetically Confirmed Statin-Induced Rhabdomyolysis: A Dual Case Report
by: Jozef Dodulík, et al.
Published: (2025-05-01)